RedHill Biopharma (RDHL) Corporate presentation summary

Corporate highlights and financials

• Focuses on U.S. commercialization and development of drugs for GI, infectious diseases, and oncology, with $4.1M net revenues and 60.6% gross margin in H1 2025.

• Strengthened U.S. commercial operations through a partnership with Cumberland Pharmaceuticals, including a $4M investment for a 30% stake in the Talicia business.

• Cash balance as of June 30, 2025, was $3M, with equity financing capacity of $31.7M as of December 2025.

Commercial product: Talicia

• Talicia (omeprazole magnesium, amoxicillin, rifabutin) is FDA-approved for H. pylori infection in adults, launched in the U.S. and UAE, and listed as a first-line option in the 2024 ACG guideline.

• Demonstrates high eradication rates (>90%) in adherent populations, with zero to minimal resistance to its antibiotic components.

• Broad U.S. managed care coverage, preferred on major formularies, and covered by government programs.

• Supported by two positive Phase 3 studies, showing superior efficacy and safety compared to standard therapies.

• Strong IP protection with patents extending to 2042 and FDA QIDP designation providing market exclusivity through 2027.

R&D pipeline overview

• RHB-102 (Bekinda): Extended-release ondansetron for GI intolerance, gastroenteritis, IBS-D, and oncology support, with positive Phase 3 and Phase 2 results.

• RHB-204: Fixed-dose oral antibiotic for Crohn's disease (MAP-positive) and pulmonary NTM disease, supported by positive Phase 3 data from RHB-104.

• Opaganib: Oral SPHK2 inhibitor in late-stage development for oncology, COVID-19, Ebola, and metabolic diseases, with positive Phase 2/3 COVID-19 and oncology data.

• RHB-107 (upamostat): Oral serine protease inhibitor for COVID-19 and oncology, with positive Phase 2 COVID-19 data.